ATRS presenting at ACR this weekend. Technicals encouraging.
The downtrend from the post-approval sell-off appears to have been broken. Now buyers are firmly establishing a floor around the $4.15 level. I'm seeing a potential rebound once ATRS presents OTREXUP clinical data this weekend.
You miss the point. It's not what ATRS will say. It's how the rheumatologists and other observers react that is important. I'd love to interview them right after the presentation. We know what ATRS has to say, but we don't know how widely OTREXUP will be adopted as a second line treatment by docs and insurance companies.
I think the shorts are holding it down into earnings, planning to push it down well into the threes on any disappointment, however small. Will add if that happens. Then I think we get a strong rebound rally.